R
Ranibizumab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Post-marketing information
Dear Healthcare Professional Letters
Subsidy Information and Financing Scheme
Standard Drug List
Active ingredient: Ranibizumab
General information
Subsidy Information and Financing Scheme
[SDL] Ranibizumab (Lucentis) Prefilled Syringe 1.65 mg/0.165 mL
[SDL] Ranibizumab (Lucentis) Injection 2.3 mg/0.23 mL
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Ranibizumab 1.65 mg/0.165 ml pre-filled syringe and 2.3 mg/0.23 ml solution for injection as an alternative to intravitreal bevacizumab for treating adults with visual impairment due to:
neovascular (wet) age-related macular degeneration;
diabetic macular oedema; and
macular oedema secondary to central or branch retinal vein occlusion
in view of an acceptable price proposal from the manufacturer.
Subsidy status
[R] Ranibizumab is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Lucentis Prefilled Syringe 1.65 mg/0.165 mL |
|
Lucentis Injection 2.3 mg/0.23 mL |
|